Month: July 2024

Company Announcement 11 July 2024 Announcement No. 20 NKT announces preliminary Q2 2024 financial figures and updates financial outlook for 2024 NKT provides preliminary financial figures for Q2 2024 and updates the financial outlook for 2024 following a positive performance in the first half of the year. NKT President and CEO Claes Westerlind says:         – Preliminary financial figures for Q2 2024 demonstrate a strong first half of the year with continued high revenue growth and increased operational EBITDA. We are satisfied with the financial performance and continue to execute on our high-voltage order backlog, as well as ongoing investments across business lines. Q2 2024: Preliminary financial figures The preliminary revenues (std. metal prices) for Q2 2024 are EUR 605m (EUR 468m in Q2 2023) and preliminary operational EBITDA...

Turin, 11th July 2024. Iveco Group N.V. (EXM: IVG) confirmed today that its financial results for the Second Quarter of 2024 will be presented on Wednesday, 24th July 2024. A live audio webcast of the conference call will begin at 11:00 am CEST / 10:00 am BST on Wednesday, 24th July 2024. Details for accessing the webcast are available at the following link: Q2 2024 Iveco Group Webcast The related press release and presentation will be posted on the corporate website at www.ivecogroup.com on Wednesday, 24th May 2024. For those unable to take part in the live session, a replay will be available in the Investors section of the company website (www.ivecogroup.com) following the conference call. Iveco Group N.V. (EXM: IVG) is the home of unique people and brands that power your business and mission to advance a more sustainable society....

Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”).  The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile.  Following the closing of the Facility, which included the settlement of existing debt obligations, Alvotech has a total gross borrowings balance of $1,035 million, and cash balance of $185 million, which includes $18 million of cash on hand, $25 million of restricted cash and estimated net proceeds of $142 million, at the time of close.  Available cash will be used to continue advancing Alvotech’s existing development pipeline,...

REYKJAVIK, Iceland, July 11, 2024 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the closing of its previously announced senior secured first lien term loan facility (the “Facility”). The closing has allowed Alvotech to refinance outstanding debt obligations, reduce the cost of capital and improve its overall debt maturity profile. Following the closing of the Facility, which included the settlement of existing debt obligations, Alvotech has a total gross borrowings balance of $1,035 million, and cash balance of $185 million, which includes $18 million of cash on hand, $25 million of restricted cash and estimated net proceeds of $142 million, at the time of close. Available cash will be used to continue...

FIXING OF COUPON FROM July 12 2024 Interest coupon for the period 12.07.2024 – 12.10.2024: DK0030497953, (RT1), 3 months CIBOR +3,6067%: 7,0067% p.a. Contact Please direct any questions regarding this announcement to: Investors and equity analysts:                           Direktør, IR Rating og ESG RapporteringMads Lerche ThinggaardMobile no. +45 2025 5469AttachmentAlm. Brand – Fixing of Coupon RT1 July 2024

PRESS RELEASE                                         Share Buyback Transaction Details July 4 – July 10, 2024 Alphen aan den Rijn – July 11, 2024 – Wolters Kluwer (Euronext: WKL), a global leader in professional information, software solutions, and services, today reports that it has repurchased 115,744 of its own ordinary shares in the period from July 4, 2024, up to and including July 10, 2024, for €17.8 million and at an average share price of €154.04. These repurchases are part of the share buyback program announced on February 21, 2024, under which we intend to repurchase shares for €1 billion during 2024. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2024Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2024 to...

VANCOUVER, BC, July 11, 2024 (GLOBE NEWSWIRE) — AMERICAN SALARS LITHIUM INC. (“AMERICAN SALARS” OR THE “COMPANY”) (CSE: USLI, OTC: ASALF, FWB: Z3P, WKN: A3E2NY) announces it has received the assay results from ALS Geochemistry Laboratory in Reno Nevada (“ALS”) from soil samples collected at the Black Rock South lithium brine project, located 72 Miles North of the Tesla Gigafactory in Nevada. Samples were processed using Boyd RSD rotary crushers and splitter with a 180-micron (80 mesh) sieve, aqua regia digestion, and 41 multi-element ICP-AES analysis (code ME-ICP41). HighlightsOut of the 38 soil samples, 33 recorded lithium concentrations of 100 ppm or higher with the highest sample recording 180.5 ppm lithium with an average grade of the 33 samples of 131 ppm across the surface of the property.Anomalous...

PRINCETON, N.J. and BENGALURU, India, July 11, 2024 (GLOBE NEWSWIRE) — Indegene today announced a strategic collaboration with Microsoft to empower global life sciences companies to scale up the adoption of purpose-built, enterprise-grade Generative AI (GenAI) services, thereby driving faster innovation at scale. Indegene and Microsoft have committed to developing resources in highly specialized and skilled medical and technology tools to co-innovate generative AI services and workflows across commercial, medical, regulatory, and clinical functions. “GenAI presents a once-in-a-decade opportunity for life sciences companies to modernize business processes and reimagine the effectiveness and efficiency of their operations throughout the value chain. Using GenAI, we’re closely working with many of our clients to solve specific business...